TürkC,KnollT,SeitzC,SkolarikosA,ChappleC,McClintonS, 2017.Medical expulsive therapy for ureterolithiasis: The EAU recommendations in 2016,Eur Urol 71 504 -7
KroczakT,ScotlandKB,ChewB,PaceKT, 2017.Shockwave lithotripsy: tech-niques for improving outcomes,World J Urol 35 1341 -6
LimKT,KimYT,LeeTY,ParkSY, 2011.Effects of tamsulosin, solifenacin, and combination therapy for the treatment of ureteral stent related discomforts,Korean J Urol 52 485 -8
CandaAE,TurnaB,CinarGM,NazliO, 2007.Physiology and pharmacology of the human ureter: Basis for current and future treatments,Urol Int 78 289 -98
WangH,ManLB,HuangGL,LiGZ,WangJW, 2016.Comparative efficacy of tamsulosin versus nifedipine for distal ureteral calculi: A meta-analysis,Drug Des Devel Ther 10 1257 -65
CoelhoA,Antunes-LopesT,GillespieJ,CvuzF, 2017.Beta-3 adrenergic receptor is expressed in acetylcholine-containing nerve fibers of the human urinary bladder: An immunohistochemical study,Neurourol Urodyn 36 1972 -80
MatsumotoR,OtsukaA,SuzukiT,ShinboH,NizunoT,KuritaY, 2013.Expression and functional role of 3 -adrenoceptors in the human ureter,Int J Urol 20 1007 -14
SebastianelliA,RussoGI,KaplanSA,Mc VaryKT,MoncadaI,GravasS, 2018.Systematic review and meta-analysis on the efficacy and tolerability of mirabegron for the treatment of storage lower urinary tract symptoms/ overactive bladder: Comparison with placebo and tolterodine,Int J Urol 25 196 -205
WanajoI,TomiyamaY,YamazakiY,KojimaM., 2011.Ureteral selectivity of intravenous beta-adrenoceptor agonists in pig model of acute ureteral obstruction: comparison of KUL-7211, a selective beta2/beta3 agonist, with isoproterenol,terbutaline, and CL-316243. Urology 77 e1 -6
MichelMC,GravasS. Safety, 2016.and tolerability of beta3- adrenoceptor agonists in the treatment of overactive bladder syndrome - insight from transcriptosome and experimental studies,Expert Opin Drug Saf 15 647 -57